Missouri judge approves Bayer’s Roundup settlement worth up to $7.25 billion
A Missouri judge approved a nationwide settlement that could cost Bayer up to $7.25 billion over claims linking Roundup to non-Hodgkin lymphoma.
A Missouri judge gave final approval Friday to a nationwide settlement that could cost Bayer up to $7.25 billion in the coming years. The deal addresses claims that exposure to Roundup, the weed killer made with glyphosate, caused non-Hodgkin lymphoma, a type of blood cancer.
The settlement covers thousands of people who have been or will be diagnosed with non-Hodgkin lymphoma. Payments could range from $10,000 to $165,000, depending on factors such as a person’s age at diagnosis and whether agricultural work or another occupation exposed them to higher levels of glyphosate.
Bayer CEO Bill Anderson called the approval a “decisive milestone” that would reduce the company’s exposure to pending and future litigation. Christopher Seeger, an attorney for the plaintiffs, said the order guarantees compensation for people who have waited more than a decade. Bayer previously agreed to pay roughly $10 billion to $11 billion to resolve more than 100,000 Roundup claims.
Earlier this year, the U.S. Supreme Court ruled in Bayer’s favor, finding that the company could be shielded from state-court lawsuits alleging it failed to warn consumers about cancer risks linked to glyphosate. Bayer, which owns Monsanto, denies that Roundup causes cancer.
The World Health Organization’s cancer agency classified glyphosate as probably carcinogenic to humans more than a decade ago. The U.S. Environmental Protection Agency has said it found no risks of concern from glyphosate use, including cancer risk, and is reviewing the evidence on human health. Bayer removed glyphosate from its U.S. residential products several years ago, but the herbicide remains in agricultural use.






Comments